Literature DB >> 11149599

Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation.

K Svensson1, R Zeidman, U Trollér, A Schultz, C Larsson.   

Abstract

To investigate a putative involvement of protein kinase C (PKC) isoforms in supporting neuroblastoma cell proliferation, SK-N-BE(2) neuroblastoma cells were transfected with expression vectors coding for the C2 and V5 regions from different PKC isoforms. These structures have been suggested to inhibit the activity of their corresponding PKC isoform. The PKC fragments were fused to enhanced green fluorescent protein to facilitate the detection of transfected cells. Expression of the C2 domain from a classical PKC isoform (PKCalpha), but not of C2 domains from novel PKCdelta or PKCepsilon, suppressed the number of neuroblastoma cells positive for cyclin A and bromodeoxyuridine incorporation. This indicates a role for a classical isoform in regulating proliferation of these cells. Among the V5 fragments from PKCalpha, PKCbetaI, and PKCbetaII, the PKCbetaI V5 had the most suppressive effect on proliferation markers, and this fragment also displaced PKCbetaI from the nucleus. Furthermore, a PKCbeta-specific inhibitor, LY379196, suppressed the phorbol ester- and serum-supported growth of neuroblastoma cells. There was a marked enhancement by LY379196 of the growth-suppressive and/or cytotoxic effects of paclitaxel and vincristine. These results indicate that PKCbetaI has a positive effect on the growth and proliferation of neuroblastoma cells and demonstrate that inhibition of PKCbeta may be used to enhance the effect of microtubule-interacting anticancer agents on neuroblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149599

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  The catalytic domain limits the translocation of protein kinase C alpha in response to increases in Ca2+ and diacylglycerol.

Authors:  Arathi Raghunath; Mia Ling; Christer Larsson
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

2.  Human cytomegalovirus pUL37x1-induced calcium flux activates PKCα, inducing altered cell shape and accumulation of cytoplasmic vesicles.

Authors:  Ronit Sharon-Friling; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

3.  ELAC (3,12-di-O-acetyl-8-O-tigloilingol), a plant-derived lathyrane diterpene, induces subventricular zone neural progenitor cell proliferation through PKCβ activation.

Authors:  Maribel Murillo-Carretero; Noelia Geribaldi-Doldán; Eugenia Flores-Giubi; Francisco García-Bernal; Elkin A Navarro-Quiroz; Manuel Carrasco; Antonio J Macías-Sánchez; Pilar Herrero-Foncubierta; Antonio Delgado-Ariza; Cristina Verástegui; Jesús Domínguez-Riscart; Mourad Daoubi; Rosario Hernández-Galán; Carmen Castro
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

4.  Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Authors:  Shadan Ali; Sana Al-Sukhun; Bassel F El-Rayes; Fazlul H Sarkar; Lance K Heilbrun; Philip A Philip
Journal:  Life Sci       Date:  2009-03-24       Impact factor: 5.037

5.  Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.

Authors:  Martin Michaelis; Florian Rothweiler; Nadine Löschmann; Mohsen Sharifi; Taravat Ghafourian; Jindrich Cinatl
Journal:  Oncotarget       Date:  2015-07-10

6.  A protein kinase Cbeta inhibitor attenuates multidrug resistance of neuroblastoma cells.

Authors:  Karin Svensson; Christer Larsson
Journal:  BMC Cancer       Date:  2003-03-26       Impact factor: 4.430

7.  Protein kinase C: an attractive target for cancer therapy.

Authors:  Barbara Marengo; Chiara De Ciucis; Roberta Ricciarelli; Maria A Pronzato; Umberto M Marinari; Cinzia Domenicotti
Journal:  Cancers (Basel)       Date:  2011-02-01       Impact factor: 6.639

8.  Molecular characterization of protein kinase C delta (PKCδ)-Smac interactions.

Authors:  Christian Holmgren; Louise Cornmark; Gry Kalstad Lønne; Katarzyna Chmielarska Masoumi; Christer Larsson
Journal:  BMC Biochem       Date:  2016-05-23       Impact factor: 4.059

9.  Workflow-driven clinical decision support for personalized oncology.

Authors:  Anca Bucur; Jasper van Leeuwen; Nikolaos Christodoulou; Kamana Sigdel; Katerina Argyri; Lefteris Koumakis; Norbert Graf; Georgios Stamatakos
Journal:  BMC Med Inform Decis Mak       Date:  2016-07-21       Impact factor: 2.796

10.  A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.

Authors:  Xueying Li; Xiaojie Fang; Su Li; Weijing Zhang; Nong Yang; Yimin Cui; He Huang; Ruiqing Cai; Xiaoting Lin; Xiaohong Fu; Huangming Hong; Tongyu Lin
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.